Effects of nano-curcumin in children with celiac disease

An investigation into the efficacy of nano-curcumin for the management of clinical symptoms and the alleviation of gastrointestinal inflammation in children with celiac disease: a pilot randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240721062501N1

Enrollment

Registered

2024-10-19

Start date

2024-10-22

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Celiac disease. Coeliac disease

Interventions

Intervention 1: Intervention group: gluten-free diet along with daily consumption of 80 mg of nanocurcumin in two separate doses for 8 weeks. Gelatin capsules contain 40 mg of curcumin in the form of

Eligibility

Sex/Gender

All

Age

5 Years to 18 Years

Inclusion criteria

Inclusion criteria: Definitive diagnosis of celiac disease based on the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) criteria Diagnosis of celiac disease of less than six months' duration Patients aged between 5 and 18 years Informed consent of the patient and legal guardian for participation

Exclusion criteria

Exclusion criteria: Cardiovascular, liver, or kidney failure Presence of other autoimmune disorders Celiac crisis requiring hospitalization within the past four weeks Acute gastroenteritis

Design outcomes

Primary

Measure	Time frame
Serum endomysial antibody IgA. Timepoint: Before the administration of curcumin and 8 weeks after the initiation of treatment. Method of measurement: Laboratory test.;Gastrointestinal symptoms score based on Gastrointestinal Symptom Rating Scale (GSRS). Timepoint: Before the administration of curcumin and 8 weeks after the initiation of treatment. Method of measurement: Gastrointestinal Symptom Rating Scale (GSRS).;Body mass index. Timepoint: Before the administration of curcumin and 8 weeks after the initiation of treatment. Method of measurement: digital scale.;Fecal calprotectin. Timepoint: Before the administration of curcumin and 8 weeks after the initiation of treatment. Method of measurement: Laboratory test.;Serum tissue transglutaminase IgA. Timepoint: Before the administration of curcumin and 8 weeks after the initiation of treatment. Method of measurement: Laboratory test.	—

Measure

Time frame

Serum endomysial antibody IgA. Timepoint: Before the administration of curcumin and 8 weeks after the initiation of treatment. Method of measurement: Laboratory test.;Gastrointestinal symptoms score based on Gastrointestinal Symptom Rating Scale (GSRS). Timepoint: Before the administration of curcumin and 8 weeks after the initiation of treatment. Method of measurement: Gastrointestinal Symptom Rating Scale (GSRS).;Body mass index. Timepoint: Before the administration of curcumin and 8 weeks after the initiation of treatment. Method of measurement: digital scale.;Fecal calprotectin. Timepoint: Before the administration of curcumin and 8 weeks after the initiation of treatment. Method of measurement: Laboratory test.;Serum tissue transglutaminase IgA. Timepoint: Before the administration of curcumin and 8 weeks after the initiation of treatment. Method of measurement: Laboratory test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahsa Mohammadzadeh

Mashhad University of Medical Sciences

MohammadzadehM4011@mums.ac.ir+98 51 3871 3801

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026